BEAT HeartBeam Inc

$BEAT omg 403 million shares traded today. If there’s continuation in volume we shall see $1+ this week, then the upgrades, then compliance met, then multi center trial, etc. so many things to move this up!

$BEAT down almost 50% from this week’s high of .95. Madness… it’s trading as if the FDA rescinded their priority designation…. They’re going to give a kickass presentation at the end of the month and reveal trial results that impressed the FDA so much that they responded within 30 days when they had 60 days to respond… 🍾🚀🍾🚀💰💰💰💰

$BEAT thinkorswim showing overnight high of .59 and low of .31 after Friday close. Super low volume so it might be nothing but strange that any number of shares can trade at those prices. There’s a pattern this stock surges towards the end of the year. Hope to see $4 again before EOY

$BEAT • The ALIGN-ACS Pilot Study (Full Data Presentation): • The Details: This study evaluated the HeartBeam System in 134 emergency department patients presenting with chest pain across two sites in Belgrade, Serbia. It compared the device directly to standard 12-lead ECGs and final discharge diagnoses to prove its accuracy in detecting heart attacks. • Status: Patient enrollment wrapped up ahead of schedule. The full, highly anticipated data results are scheduled to be presented at the TCT 2026 conference in San Diego (October 31 – November 3, 2026).

$BEAT what are peoples price targets? Mine is short term (2026) we hit $1.20 comfortably. Long term, 3-5$ and beyond.

$BEAT lets be clear here folks. This product has the potential to save lives and impact the world. The next step relies on how positive the data is (which the signs are already pointing to it being extremely good). Once the results are out, there could be strategic partnerships in place to get this product to market. Its extremely exciting and the anticipation is all part of the fun of these volatile stocks. Im happy to invest a decent chunk in this. Lets make some money people. Lets gooooo!😎

$BEAT Inside buying at .80 just a few months ago, plus the possibility of a partner announcement, and FDA trials...........Holding long term

$BEAT Glad yesterday’s rally put this one on my radar. Major catalysts ahead and plenty of upside potential. Extremely bullish! 🎯 $3

$BEAT I believe this stock has the near team ability to reach the previous all time high of over 5 dollars a share. Given the correct news and timing I believe, my personal opinion, that this is archivable sooner than later.

$BEAT Which one is going to be? Or is it going to be all of them with funding for the studies needed to get FDA approval for heart attack detection at home or ambulance. If emt services were to have access to the tech they wouldn't even have to move the patients before putting them in an ambulance. At rest or semi rested state would provide much more data than the excited state from screaming sirens and the comotion.

$BEAT Almost every stock went down Friday but this one didn't. That's a good sign for next week.

$BEAT Those that keep crying dilution, the max potential dilution BEAT has is an additional 42.39 million shares for a total outstanding (possibility, not current) of 98.739 million shares. Their high over the last year was $3.44 (closing, $4.00 intraday), that equates to $1.40 a share fully diluted to match year high. And that high didn't have the FDA approval. SO I FULLY CALL BS on the dilution as a reason to be bearish. This puppy has lots of room to run!

$BEAT has a very quiet 7% share price gain today with a lot more upside potential with the share price in the future. This is a buy and hold long term stock. Swing traders, day traders and penny profit flippers will miss out on huge profits in the future. HOLD LONG NOW & HOLD STRONG NOW!!

$BEAT HeartBeam announced that it received the FDA Breakthrough Device Designation for its HeartBeam System on October 5, 2026. The regulatory agency granted the designation surprisingly quickly, approving the company's request within 30 days of submission—well ahead of the FDA's standard 60-day statutory review window

$BEAT Just so you know, if this were truly a breakthrough device, it wouldn’t be trading at $0.50. The market can be wrong, especially with penny stocks, but it’s usually not that far off.

$BEAT Branislav “brains” has a combined 30 years as a Dr and business man. He will see this through to success and sell. What a nice man. 🥊 knock it home

HeartBeam shares after the FDA granted Breakthrough Device Designation to its HeartBeam System, designed to help physicians assess potential heart-attack symptoms remotely, including in patients’ homes. The FDA granted the designation in just 30 days, ahead of its standard 60-day review period, signaling strong regulatory interest. The designation provides HeartBeam with prioritized FDA review and closer regulatory collaboration while potentially supporting accelerated Medicare coverage pathways. The company estimates a roughly $15 billion market for heart-attack assessment within a broader cardiac platform opportunity exceeding $40 billion. The designation was supported by data from the 134-patient ALIGN-ACS pilot study, with full results expected at the TCT conference later this month, providing a near-term catalyst. Shares reached an intraday high of $0.939 before paring gains, while the broader Nasdaq and S&P 500 rose 0.8% and 0.5%, respectively. $BEAT

$BEAT nice little reversal there. This wouldnt get driven down too low following the news and interest. I think we can 5x from here comfortably. My money is staying in and i will enjoy the journey with the ups and downs along the way

$BEAT this company has a market cap of only 22 million, and in the near future it will have sales of hundreds of millions. I say buy it, be patient, forget about it, put it away, and our day will come 

$BEAT not only they will present ALIGN-ACS data at TCT but they will disclose HEADSTART-ACS, study of heart attack detection from 500 patients in Indonesia, in coming weeks. Stay strong, know what you own.